A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT07123415 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

110

Enrollment

INDIV

Sponsor class

Conditions

Advanced Solid Cancer
Advanced Solid Tumor (Phase 1)

Interventions

DRUG: APX-343A
DRUG: Pembrolizumab

Sponsor

Aptabio Therapeutics, Inc.